Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells DMR profiles for monitoring oncogenic signaling pathways in cancer cells

Journal of Receptors and Signal Transduction

Volumn 29, Issue 3-4, 2009, Pages 182-194

  Du, Yuhong ^a   Li, Zijian ^a   Li, Lian ^a   Chen, Z ^a   Sun, Shi Yong ^a   Chen, Peifang ^a   Shin, Dong M ^a   Khuri, Fadlo R ^a   Fu, Haian ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dynamic mass redistribution (DMR); Epidermal growth factor (EGF) receptor; High throughput screening.; Label free; Oncogenic pathway

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; WORTMANNIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ADENOCARCINOMA; OPTICAL BIOSENSOR; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; DRUG EFFECT; GENETIC PROCEDURES; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 70350633466     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890902976933     Document Type: Article

References (34)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
2. Seger R, Yarden Y, Kashles O, Goldblatt D, Schlessinger J, Shaltiel S. The epidermal growth factor receptor as a substrate for a kinase-splitting membranal proteinase. J Biol Chem 1988;263(7):3496-3500 (Pubitemid 18072813)
3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev 2005;5(5):341-354
4. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000;19(13):3159-3167
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127-137
6. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501.
8. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507.
9. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195-217.
10. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366(1):2-16.
11. Saba NF, Khuri FR, Shin DM.Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park) 2006;20(2):153-61; discussion 62, 66, 69 passim.
12. Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 2004; 10(12 Pt 2):4249s-53s.
13. Harichand-Herdt S, Ramalingam SS. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Semin Thorac Cardiovasc Surg 2008;20(3):217-223
14. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824-832
15. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-7356
16. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 2007;8 Suppl 2:S79-85.
17. Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006;20(5 Suppl 2):15-25.
18. Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal 2008;8:909-919
19. Xi B, Yu N, Wang X, Xu X, Abassi YA. The application of cellbased label-free technology in drug discovery. Biotechnol J 2008;3(4):484-495
20. Fang Y. Label-free cell-based assays with optical biosensors in drug discovery. Assay Drug Dev Technol 2006;4(5): 583-595
21. Fang Y, Ferrie A, Fontaine N, Ki Yuen P. Optical biosensors for monitoring dynamic mass redistribution in living cells mediated by epidermal growth factor receptor activation. Conf Proc IEEE Eng Med Biol Soc 2005;1:666-669 (Pubitemid 46228952)
22. Fang Y, Ferrie AM, Fontaine NH, Mauro J, Balakrishnan J. Resonant waveguide grating biosensor for living cell sensing. Biophys J 2006;91(5):1925-1940
23. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4(2):67-73.
24. Fang Y, Ferrie AM, Fontaine NH, Yuen PK. Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal Chem 2005;77(17):5720-5725 (Pubitemid 41266070)
25. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56(15):3540-3545
26. Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 2006;26(5):569-594
27. Fang Y, Ferrie AM, Li G. Probing cytoskeleton modulation by optical biosensors. FEBS Lett 2005;579(19):4175-4180
28. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007;43(1):35-45.
29. Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 2004;58(3):991-1002.
30. Muller S, Su L, Tighiouart M, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 2008;113(1):97-107.
31. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62(20):5749-5754
32. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57(21):4838-4848
33. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14(3):295-304.
34. Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y, Sano D. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep 2008;19(1):65-71.